JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blum, J. J.
Right arrow Articles by Scholes, N. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blum, J. J.
Right arrow Articles by Scholes, N. W.
Journal of Pharmacology And Experimental Therapeutics, Vol. 121, Issue 4, 477-486, 1957
Copyright © 1957 by American Society for Pharmacology and Experimental Therapeutics

THE MECHANISM OF ACTION OF RYANODINE ON SKELETAL MUSCLE

Jacob J. Blum 1, Richard Creese 1, Donald J. Jenden 1, and Norman W. Scholes 1

1 Naval Medical Research Institute and Department of Pharmacology, University of California at Los Angeles

An attempt has been made to determine the site and mechanism of action of ryanodine in skeletal muscle, where it causes an irreversible contracture. Evidence is presented that it does not act at the neuromuscular junction and that the resting membrane potential of muscle is unaffected. It does not alter the ATPase activity or the light scattering response of Myosin B to ATP or the ATP induced shortening of glycerol-treated muscle fibers. The existence of a latent period before the development of contracture, the duration of which is inversely related to the concentration of ryanodine, together with other evidence, suggests that the characteristic action of ryanodine may result from the progressive inactivation or destruction of a key entity necessary for contraction and relaxation.

Submitted on July 12, 1957




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
P. M. Hopkins
Malignant hyperthermia: advances in clinical management and diagnosis
Br. J. Anaesth., July 1, 2000; 85(1): 118 - 128.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1957 by the American Society for Pharmacology and Experimental Therapeutics.